Insulet, Guardant Health, agilon health, Evolent Health, and Myriad Genetics Stocks Trade Up, What You Need To KnowA number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
Why Myriad Genetics (MYGN) Stock Is Up TodayShares of genetic testing company Myriad Genetics (
NASDAQ:MYGN)
jumped 0.4% in the afternoon session after the company shared a positive outlook, projecting significant revenue from its hereditary cancer testing division and outlining its growth targets for the coming years. Myriad Genetics projected approximately $370 million in revenue from this testing segment for the year, accounting for about 45% of its total sales. The company also targeted a growth rate in the high single-digits to low double-digits over the next three to five years. To help achieve these goals, it was supported by a $35 million investment aimed at enhancing its commercial capabilities.
Q3 Earnings Roundup: Myriad Genetics (NASDAQ:MYGN) And The Rest Of The Therapeutics SegmentEarnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Myriad Genetics (
NASDAQ:MYGN) and its peers.
1 High-Flying Stock with Solid Fundamentals and 2 We QuestionExpensive stocks often command premium valuations because the market thinks their business models are exceptional.
However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.
Merck, Elanco, Myriad Genetics, Neogen, and Cigna Shares Are Soaring, What You Need To KnowA number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. This divergence was stark: the tech-heavy Nasdaq struggled, losing 0.2%, while the Dow rallied.
This shift away from tech was triggered by a series of negative catalysts in the AI sector. AI cloud provider CoreWeave slid on disappointing guidance, while chip darling Nvidia pulled back after SoftBank sold its stake. This "hurt the AI trade," dragging down related names like Micron and Oracle.
As capital left tech, it sought safety in "higher quality" defensive names. Health care giants like Merck, Amgen, and Johnson & Johnson saw significant buying, boosting the Dow.
Myriad Genetics to Participate in Upcoming Investor Healthcare ConferencesSALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (
NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences.
The Top 5 Analyst Questions From Myriad Genetics’s Q3 Earnings CallMyriad Genetics’ third quarter saw revenue and adjusted profit in line with Wall Street expectations, but the market reacted negatively due to ongoing challenges in average revenue per test and operational headwinds. Management cited continued strong volume growth in the oncology segment, particularly for its MyRisk hereditary cancer test, as a positive. CEO Samraat Raha noted, “MyRisk continues to see positive demand in the market and supports our profitable growth journey,” while also acknowledging the impact of payer mix and policy changes. The company faced pressure from reduced coverage for its GeneSight mental health test and a divested European business, but highlighted improved execution and stabilization in core test volumes.
Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual ConferenceSALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (
NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and reproductive genetic testing at the National Society of Genetic Counselors (NSGC) 44th Annual Conference. Myriad’s MyRisk® Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel® Prenatal Screen and Foresight® Carrier Screen are among the products included in the new studies to be shared.
Why Myriad Genetics (MYGN) Stock Is Down TodayShares of genetic testing company Myriad Genetics (
NASDAQ:MYGN)
fell 19.3% in the morning session after it reported mixed third-quarter results that were overshadowed by a weak earnings outlook.
MYGN Q3 Deep Dive: Oncology Growth and Product Launches Offset Market HeadwindsGenetic testing company Myriad Genetics (
NASDAQ:MYGN) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 3.6% year on year to $205.7 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $823 million at the midpoint. Its non-GAAP profit of $0 per share was $0.01 above analysts’ consensus estimates.
Myriad Genetics’s (NASDAQ:MYGN) Q3 Earnings Results: Revenue In Line With Expectations But Stock DropsGenetic testing company Myriad Genetics (
NASDAQ:MYGN) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 3.6% year on year to $205.7 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $823 million at the midpoint. Its non-GAAP loss of $0 per share was $0.01 above analysts’ consensus estimates.
What To Expect From Myriad Genetics’s (MYGN) Q3 EarningsGenetic testing company Myriad Genetics (
NASDAQ:MYGN)
will be reporting results this Monday after the bell. Here’s what to expect.
1 Stock Under $10 Worth Your Attention and 2 Facing Challenges Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums).
That doesn’t mean they’re bargains though, and we urge investors to be careful as many have risky business models.
Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025SALT LAKE CITY, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (
NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2025 earnings conference call at 4:30 pm ET on Monday, Nov. 3, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the third quarter 2025.
2 Unpopular Stocks That Deserve a Second Chance and 1 That UnderwhelmWall Street has issued downbeat forecasts for the stocks in this article.
These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus PanelThe Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations
3 Cash-Burning Stocks with Open QuestionsWhile some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth.
A high cash burn rate without a strong balance sheet can leave investors exposed to significant downside.
Myriad Genetics, Omnicell, Globus Medical, Repligen, and Teleflex Stocks Trade Down, What You Need To KnowA number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
